J Adhes Dent. 2023 Oct 6;25:177-186. doi: 10.3290/j.jad.b4478817.
This follow-up of a randomized clinical split-mouth study aimed to investigate the influence of selective enamel etching on the long-term clinical performance of partial ceramic crowns (PCCs) luted with a self-adhesive resin cement.
43 patients received two PCCs (Vita Mark II; Cerec 3D) each for the restoration of extensive lesions with multiple cusp coverage, inserted with a self-adhesive resin cement (RelyX Unicem, RXU). Using a split-mouth design, one PCC received additional selective enamel etching (RXU+E) and one did not (RXU-E). Patients were clinically evaluated at baseline and after up to 15 years (median observation period 176 months) using modified USPHS and FDI criteria. The data were analyzed non-parametrically (chi-squared tests, α = 0.05). Clinical survival of all restorations after 15 years was evaluated using the Kaplan-Meier analysis.
After 15 years, 19 patients were available for clinical assessment (recall rate: 56%). Kaplan-Meier analysis showed a cumulative survival of 78.1% for RXU+E and of 42.9% for RXU-E, indicating a significantly higher survival rate for RXU+E (p = 0.004). Regarding the clinical performance of PCCs available for the 15-year evaluation, no statistically significant differences were found between RXU+E and RXU-E using modified USPHS and FDI criteria. Both groups revealed significant deterioration over time regarding surface luster, marginal adaptation, and marginal discoloration. RXU+E resulted in significantly inferior anatomic form over time and a significant improvement in post-operative hypersensitivity compared to baseline.
For posterior PCCs, selective enamel etching can be recommended based on higher survival rates after 15 years. Clinically, deterioration due to aging is similar in both groups.
本研究为一项随机临床分口研究的随访,旨在探究选择性釉质酸蚀对采用自粘接树脂水门汀黏结的部分陶瓷冠(PCC)长期临床性能的影响。
43 名患者因多个牙尖覆盖的广泛牙体缺损接受了两颗 PCC(Vita Mark II;Cerec 3D)修复,采用自粘接树脂水门汀(RelyX Unicem,RXU)黏结。采用分口设计,一颗 PCC 进行了选择性釉质酸蚀(RXU+E),另一颗未进行(RXU-E)。使用改良的 USPHS 和 FDI 标准,患者在基线时和 15 年时(中位观察期 176 个月)进行临床评估。数据分析采用非参数检验(卡方检验,α=0.05)。采用 Kaplan-Meier 分析评估所有修复体 15 年后的临床存活率。
15 年后,19 名患者可进行临床评估(召回率:56%)。Kaplan-Meier 分析显示,RXU+E 的累积存活率为 78.1%,RXU-E 的为 42.9%,表明 RXU+E 的存活率显著更高(p=0.004)。对于可进行 15 年评估的 PCC 临床性能,采用改良的 USPHS 和 FDI 标准,RXU+E 和 RXU-E 之间未发现统计学显著差异。两组在表面光泽度、边缘适应性和边缘变色方面均随时间显著恶化。RXU+E 的解剖形态随时间推移显著恶化,与基线相比,术后超敏反应显著改善。
对于后牙 PCC,选择性釉质酸蚀可基于 15 年后的更高存活率推荐使用。临床方面,两组由于老化导致的恶化情况相似。